About Combinature Biopharm
Combinature Biopharm AG optimizes and develops natural product-based pharmaceuticals for preclinical and clinical development. The focus of its proprietary product development is on anti-infectives. The company uses a unique "combinatorial biosynthesis" technology platform that combines genetic manipulations of the biosynthetic blueprint with the use of enzymes to achieve specific structural modifications of natural products. The company employs over 20 people and is working on a broad portfolio of preclinical development candidates. A lipopeptide antibiotic, which has a novel mechanism of action and can therefore be used to treat serious infections caused by multidrug-resistant pathogens in hospitals, is about to enter Phase I clinical trials, scheduled for 2006. Combinature is successfully pursuing the licensing of further antibiotic development candidates and is working with leading pharmaceutical and biotechnology companies.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Focus : Manufacturer
- Industry : Pharma
